NEWTOWN, Pa., Sept. 29, 2022 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech firm targeted on neurological wellness, immediately introduced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will current at the ROTH Capital Partners Inaugural Healthcare Opportunities Conference, as follows:
| Date: | Thursday, October 6, 2022 |
| Time: | 8:45 AM ET |
| Location: | The Yale Club, New York, NY |
Investors and attendees who would love to schedule a 1-on-1 assembly with Helius administration are requested to contact their Roth Capital consultant to prepare a gathering.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a number one neurotech firm in the medical machine area targeted on neurologic deficits utilizing non-implantable platform applied sciences that amplify the mind’s capability to compensate and promote neuroplasticity, enhancing the lives of individuals coping with neurologic illnesses.
The Company’s first industrial product is the Portable Neuromodulation Stimulator (PoNS®). For extra info, go to www.heliusmedical.com.
About the PoNS Device and PoNS Therapy
The Portable Neuromodulation Stimulator (PoNS) is an progressive non-surgical medical machine, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the floor of the tongue to enhance steadiness and gait. The PoNS machine is indicated to be used in the United States as a short-term therapy of gait deficit due to mild-to-moderate signs from a number of sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic train program in sufferers 22 years of age and over by prescription solely. Helius is advancing PoNS post-approval analysis in MS by means of a not too long ago launched Therapeutic Experience Program (TEP) designed to associate with neurologists and neurorehabilitation therapists at 10-12 US facilities of excellence, who specific an curiosity in changing into “early adopters” of PoNS remedy. For extra info go to www.ponstherapy.com.
PoNS can be approved on the market in Canada for 2 indications: (i) to be used as a short-term therapy (14 weeks) of persistent steadiness deficit due to mild-to-moderate traumatic mind harm (“mmTBI”) and is to be used at the side of bodily remedy; and (ii) to be used as a brief time period therapy (14 weeks) of gait deficit due to gentle and reasonable signs from MS and is to be used at the side of bodily remedy. PoNS can be approved on the market in Australia for brief time period use by healthcare professionals as an adjunct to a therapeutic train program to enhance steadiness and gait.
Investor Relations Contact
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: [email protected]
